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Abstract
Chronic hepatitis B virus (HBV) infection is caused by inadequate anti-viral immunity. Activation of plasmacytoid dendritic
cells (pDC) leading to IFNa production is important for effective anti-viral immunity. Hepatitis B virus (HBV) infection lacks
IFNa induction in animal models and patients and chronic HBV patients display impaired IFNa production by pDC.
Therefore, HBV and HBV-derived proteins were examined for their effect on human pDC in vitro. In addition, the in vitro
findings were compared to the function of pDC derived from chronic HBV patients ex vivo. In contrast to other viruses, HBV
did not activate pDC. Moreover, HBV and HBsAg abrogated CpG-A/TLR9-induced, but not Loxoribine/TLR7-induced, mTOR-
mediated S6 phosphorylation, subsequent IRF7 phosphorylation and IFNa gene transcription. HBV/HBsAg also diminished
upregulation of co-stimulatory molecules, production of TNFa, IP-10 and IL-6 and pDC-induced NK cell function, whereas
TLR7-induced pDC function was hardly affected. In line, HBsAg preferentially bound to TLR9-triggered pDC demonstrating
that once pDC are able to bind HBV/HBsAg, the virus exerts its immune regulatory effect. HBV not only directly interfered
with pDC function, but also indirectly by interfering with monocyte-pDC interaction. Also HBeAg diminished pDC function
to a certain extent, but via another unknown mechanism. Interestingly, patients with HBeAg-positive chronic hepatitis B
displayed impaired CpG-induced IFNa production by pDC without significant alterations in Loxoribine-induced pDC
function compared to HBeAg-negative patients and healthy controls. The lack of activation and the active inhibition of pDC
by HBV may both contribute to HBV persistence. The finding that the interaction between pDC and HBV may change upon
activation may aid in the identification of a scavenging receptor supporting immunosuppressive effects of HBV and also in
the design of novel treatment strategies for chronic HBV.
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Introduction
Hepatitis B virus (HBV) infects the liver as primary target and
may elicit progressive liver injury leading to increased risk of
developing liver cirrhosis, liver failure and liver cancer [1].
Chronic infection with HBV is the result of an ineffective anti-viral
immune response towards the virus [1–3]. The exact mechanism
by which HBV escapes immunity is still not known.
In general, the immune system is alerted and evokes a number
of mechanisms that are aimed at eradicating the viral attack
immediately following viral infection. The initial response to viral
infection is the rapid release of type I interferons (IFN), IFNa and
IFNb, which is observed for most viruses studied [4]. These IFN
enhance the first defense against viral infections and modulate
both innate and adaptive immune cells. Indications of the role of
type I IFN during HBV infection are mostly based on studies in
chimpanzees, since this is the only animal that can be infected with
HBV. In sharp contrast to other viruses including hepatitis C virus,
chimpanzees infected with HBV showed a complete lack in the
induction of type I IFN and in IFN-response genes during the
early stages of infection [5]. It is difficult to study the early events
of acute HBV infection in humans. Nevertheless, it was recently
shown that type I IFN responses are also lacking in acute HBV
patients [6].
Plasmacytoid dendritic cells (pDC) are the principal producers
of type I IFN and play a central role in immune responses against
viral infections [7,8]. pDC respond to viruses and other pathogens
primarily through the recognition of pathogen-associated molec-
ular patterns by two intracellular Toll-like receptors (TLR), TLR7
and TLR9, which recognizes single stranded RNA and unmethy-
lated DNA motifs, respectively [9,10]. TLR-triggering activates
pDC to rapidly produce high levels of type I interferons, but also
other cytokines, including TNF-a and IL-6, and cell surface co-
stimulatory molecules. In this way pDC exert a direct anti-viral
effect by producing factors that inhibit viral replication, but they
also activate natural killer (NK) cells and T lymphocytes allowing
further priming and regulation of anti-viral immunity [7,11,12].
Circulating blood pDC numbers seem to be unaffected by
HBV, but functional deficits in pDC from chronic HBV patients
including impaired IFN-a production have been reported [13].
Recently, it was reported that patient-derived HBsAg binds to
human pDC in vitro and impairs TLR9-induced IFNa production
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chronic HBV patients [15,16] indicates that at least the whole
virus and not only HBsAg interacts with pDC. Whether also HBV
particles and/or other HBV-derived proteins present in patient’s
circulation interfere with pDC function is not known. Given the
central role that pDC play in antiviral immune responses,
understanding the mechanisms whereby pDC interact with and
respond to HBV may provide fundamental insights into the
regulation of HBV-specific immunity and the development of
HBV chronicity. Therefore, the present study investigated the
effect of HBV as whole particles and HBV-derived proteins, i.e.
HBcAg, HBeAg and HBsAg, on direct and indirect anti-viral
functions of pDC.
Results
HBV does not activate pDC
HBV is a DNA virus that replicates via an RNA intermediate.
In theory, HBV may thus be able to activate pDC via TLR7,
TLR9 and/or cytosolic pattern recognition receptors. However,
no evidence exists that HBV replicates in pDC, which makes the
direct activation of pDC by HBV via TLR7 maybe not very likely.
Known synthetic and viral TLR7 and TLR9 ligands including
Influenza virus, HSV-1, CpG and to a lesser extent Lox induced
pDC to produce IFNa (Fig. 1A). In contrast, HBV did not give rise
to IFNa producing pDC (Fig. 1). Similar data were observed for
TNFa.
Though HBV did not induce cytokines, the virus might induce
pDC maturation. Whereas HSV-1 and Influenza virus as well as
the synthetic TLR7 and TLR9 ligands upregulated the expression
of CD40, CD80, CD86, and to a minor extent HLA-DR, HBV
only marginally increased the expression of HLA-DR without
affecting the expression of CD40, CD80 and CD86 (Table 1).
HBV impairs CpG-induced pDC maturation and function
To determine whether HBV mainly behaves as a stealth virus
for pDC, or that it has an active role in the regulation of pDC
function. pDC were activated with HSV-1, Lox and Influenza
virus either with or without HBV. HBV significantly inhibited
HSV-induced CD40 expression. Most pronounced inhibitory
effects of HBV were observed for CpG-induced pDC maturation
as demonstrated by diminished CD40, CD80 and CD86
upregulation (Table 1). As was found for the minor increase in
HLA-DR expression upon HBV in non-stimulated cultures, HBV
slightly upregulated HLA-DR expression in stimulated pDC
cultures, which was not significant for the individual stimuli, but
was significantly elevated by HBV when combining all different
stimuli.
HBV did not affect the IFNa production induced by these
stimuli (Fig. 2A), except for CpG-induced IFNa, which was dose-
dependently inhibited by HBV as assessed by intracellular flow
cytometry after 5h (Fig. 2A) and ELISA after 24h (Fig. 2AB) and
48h (data not shown) of culture. Since HSV-1 can trigger TLR9,
but also other innate immune receptors, and Lox and Influenza
are known to trigger TLR7, the inhibitory effect of HBV seemed
to be restricted to TLR9 triggering.
To assess whether HBV interferes with IFNa production at the
transcriptional level, pDC were stimulated with CpG in the
presence or absence of HBV, and analysed by intracellular flow
cytometry for the presence of phosphorylated IRF7, the
transcription factor involved in the transcription of IFNa genes.
HBV reduced CpG-induced IRF7 phosphorylation (Fig. 2C) and
in line also reduced IFNa2 and IFNa8 mRNA levels as detected
by quantitative RT-PCR analysis (Fig. 2DE).
HBV inhibits cytokine production and NK cell activation
by pDC
Next to IFNa, pDC produce more cytokines involved in anti-
viral immunity. According to previous studies, CpG stimulation
resulted in the induction of TNFa, IP-10 and IL-6 (Fig. 3A–C), but
not IL-8 (Fig. 3D). HBV inhibited TNFa, IP-10 and IL-6
production, whereas IL-8 production was not significantly affected
(Fig. 3A–D). In line with this cell-culture derived HBV, also
patient-derived HBV particles inhibited CpG-induced production
of IFNa (3E), TNFa (F) and IL-6 (G) by pDC.
Besides the direct antiviral effects of the cytokines, pDC also
have indirect anti-viral activities via the activation NK cells [12].
Addition of CpG-activated pDC to NK cells resulted in strong NK
cell activation as demonstrated by the upregulation of CD69,
CD25 and the induction of IFNc production (Fig. 3HI; data not
shown). Although HBV did not affect pDC-induced upregulation
of CD25 on NK cells (Fig. 3H), NK cell-derived IFNc production
Figure 1. HBV does not activate pDC. A: PBMC were stimulated
with CpG and analysed for IFNa production by pDC as described in
Materials and Methods. Shown is a representative FACS plot of PBMC
stained for CD123 and BDCA-4 to identify pDC and the detection of
IFNa positive cells within this pDC-gate. B: IFNa and TNFa producing
pDC within PBMC cultured in the presence or absence of HepG2.215-
derived HBV, CpG, HSV-1, Lox or Influenza are presented as mean6SEM
of 10 independent experiments.
doi:10.1371/journal.pone.0015324.g001
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derived from non-transfected HepG2 cells served as a control and
did not influence pDC function (data not shown).
Monocytes support immune regulatory effect of HBV on
pDC
Although on a per cell basis more HBV particles seemed to be
required for significant immune regulatory effects on purified pDC
compared to pDC present in PBMC cultures, the number of HBV
genome equivalents per pDC in pure pDC cultures compared to
the 60.3% pDC present in total PBMC cultures was even 10–50
times less (Fig. 2B, 4A). Nevertheless, the relative inhibition of
CpG-induced IFNa producing pDC was more pronounced when
whole PBMC cultures were exposed to HBV (Fig. 4B). This was
not simply due to positive selection on BDCA4 as suggested before
[17], since negative pDC selection revealed similar results (data
not shown). A role for IL-10 produced by other cell types as an
explanation for the stronger inhibition found in total PBMC
cultures could also be excluded since neutralizing IL-10 or its
receptor neither changed IFNa production nor TNFa production
by pDC (Fig. 4C; data not shown).
To identify the cell type responsible for the enhanced IFNa
production by pDC in total PBMC cultures, purified pDC were
compared with purified pDC supplemented with CD3
+, CD14
+,
CD19
+, or CD56
+ cells. Only addition of monocytes to pDC
enhanced the frequency of IFNa-producing and pDC (Fig. 4D;
data not shown). This extra monocyte-mediated IFNa production
by pDC was completely abolished by HBV (Fig. 4D). Monocytes
also enhanced the frequency of TNFa producing pDC upon
stimulation with CpG, but to a lesser extent compared to IFNa
(Fig. 4E). This resulted in a significantly enhanced inhibitory effect
of HBV on IFNa-producing pDC in the presence of monocytes
(33.464.8% inhibition by HBV for pDC vs 64.6612.2% for
pDC+mono), but a relatively unaltered rate of inhibition of TNFa-
producing pDC in the presence of monocytes (58.2612.9% for
pDC, 63.1611.0% HBV-induced inhibition for pDC+mono).
These data indicate that the supporting function of monocytes
regarding TLR9-induced cytokine production, especially IFNa,i s
abrogated by HBV.
HBeAg and HBsAg, but not HBcAg diminish pDC function
Next to whole virus also HBV-derived proteins present in
patients’ circulation, including HBeAg and HBsAg, may affect
pDC function [18]. Therefore HBsAg, HBcAg, and HBeAg were
investigated for their effect on IFNa production. Exposure of
pDC to the viral proteins alone, did not induce IFNa produc-
tion (data not shown). Interestingly, dose response studies revealed
that HBeAg and especially HBsAg, but not HBcAg dose-
dependently reduced CpG-induced IFNa production by pDC
(Fig. 5A).
Similar to the effect of whole virus, HBsAg inhibited CpG-
induced TNFa, IP-10 and IL-6 production without significantly
altering the production of IL-8 (Fig. 5B–E). HBeAg also reduced
TNFa production, but did not significantly influence the secretion
of the other cytokines. HBcAg did not modulate pDC function
(Fig. 5). Of note, neither HBV nor its viral proteins reduced pDC
viability as determined by flow cytometric analysis of intracellular
active caspase-3 as well as the binding of Annexin-V and 7AAD
(data not shown). In addition, experiments performed in the
presence of polymyxin B to neutralize possible non-detectable
levels of contaminating endotoxins did not affect the regulatory
effects of HBV or the viral proteins (data not shown).
HBeAg positive chronic HBV is associated with impaired
CpG-induced pDC function
To investigate whether pDC circulating in chronic HBV present
a similar functional profile as observed after in vitro exposure to
HBV or its viral proteins, CpG and Lox-induced IFNa production
by pDC of chronic HBV patients was compared to the IFNa
production by pDC of age and gender-matched healthy controls
(Table 2). Impaired IFNa production by pDC from chronic HBV
patients have been described before (reviewed in Woltman et al.
[13]), but a comparison between TLR7 and TLR9 stimulation is
lacking. Both CpG and Lox-stimulation significantly induced
IFNa production as measured by ELISA and intracellular flow
cytometry (Fig. 6A–D), albeit for Lox to a much lesser extent.
Interestingly, only the CpG-induced IFNa production was
significantly reduced in HBV patients compared to healthy
controls, as was found for the in vitro effects of HBV. Additionally,
when comparing HBeAg positive with HBeAg negative patients,
we found that especially HBeAg-positive patients displayed a
defect in the CpG-induced IFNa production (Fig. 6BD). This
more pronounced impaired IFNa producing capacity of pDC
from HBeAg positive patients may reflect the immunosuppressive
effect of HBeAg, as demonstrated in the in vitro experiments, but
may also be a more indirect effect of the significant higher viral
Table 1. Effect of HBV on pDC maturation.
CD40 CD80 CD86 HLA-DR
ctr HBV ctr HBV ctr HBV ctr HBV
Medium 6.861.7 5.060.1 23.369.4 17.466.0 46.4621.1 34.5615.6 791.26385.1 993.46396.6
HBV 5.060.1 nd 17.466.0 nd 34.5615.6 nd 993.46396.6 nd
CpG 107.1615.1 32.265.3* 89.2625.4 59.9626.4 121.5633.2 46.9620.4* 911.26256.8 1250.66419.4
HSV 61.5621.0 49.6619.2* 37.7612.8 41.7619.2 71.8627.0 84.7641.7 836.96206.1 1109.56425.0
Lox 44.262.5 44.265.3 72.7620.7 89.1627.4 100.8620.5 114.7632.1 1136.16225.9 1368.46377.4
Influenza 153.5623.5 142.2619.1 90.269.7 89.1611.1 169.2625.2 137.369.7 779.86158.3 855.96174.4
To investigate possible pDC activation by HepG2.215-derived HBV in comparison with other pDC stimuli, PBMC were cultured in the presence or absence of HBV (100
geq/cell), CpG, HSV-1, Lox or Influenza (see ‘ctr’ lane). To investigate the immune regulatory effect of HBV on pDC maturation induced by other known pDC activating
ligands, PBMC were cultured with or without CpG, HSV-1, Lox or Influenza in the presence (‘HBV’ lane) or absence (‘ctr’ lane) of HBV (100 geq/cell). After 24h, cells were
harvested and the expression of CD40, CD80, CD86 and HLA-DR on pDC was determined by flow cytometry. Data are presented as mean6SEM fluorescent intensity of 3
independent experiments with different donors. Similar data were observed for purified pDC (not shown).
*p,0.05, paired t-test; nd=not done.
doi:10.1371/journal.pone.0015324.t001
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When investigating a possible relation between the IFNa
producing capacity and viral load or ALT, we found that serum
HBV-DNA levels did not correlate to IFNa production (data not
shown), whereas serum ALT levels significantly correlated with
IFNa (Fig. 6E).
Figure 2. HBV dose-dependently inhibits CpG-induced transcription of IFNa in pDC. A: IFNa production by pDC cultured in medium, CpG,
HSV-1, Lox or Influenza with or without HepG2.215-derived HBV was determined by flow cytometry or ELISA. Mean6SEM of 3 independent
experiments. B: CpG-activated pDC were cultured with different doses of HepG2.215-derived HBV. IFNa production determined by ELISA is presented
as mean6SEM of 16 independent experiments with different donors. C: pDC were cultured with CpG in the presence or absence of HepG2.215-
derived HBV for 3h. Data present the mean6SEM percentage of cells positive for phosphorylated IRF7 from 5 independent experiments. DE: pDC
were cultured with CpG in the presence or absence of HepG2.215-derived HBV for 2 or 4h. Data represent IFNa2( DE) and IFNa8( E) mRNA levels
normalized to GAPDH and are representative for 6 experiments (D) or show the mean6SEM IFNa mRNA levels relative to cultures without HBV (n=6)
(E). *p,0.05, **p,0.01, p,0.001, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0015324.g002
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15324Figure 3. HBV inhibits cytokine production and pDC-induced NK cell activation. ABCD: Purified pDC were cultured with CpG in the
presence or absence HepG2.215-derived HBV. Supernatants were analysed for TNFa (A), IP-10 (B), IL-6 (C) and IL-8 (D). Data demonstrate mean6SEM
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To investigate the specific interference of HBV with CpG-
induced pDC function in more detail, intracellular TLR7 and
TLR9 signalling was examined. It was recently found that TLR/
Myeloid differentiation primary response protein 88 (MyD88)-
induced IFNa production by pDC requires mTOR activation [19]
resulting in phosphorylation of IRF7 and subsequent IFNa gene
transcription. To assess whether HBV interferes with mammalian
target of rapamycin (mTOR)-induced IRF7 phosphorylation,
pDC were stimulated with or without CpG or Lox in the presence
or absence of HBV, and analysed for the expression of
phosphorylated S6, a downstream target of mTOR [20]. Baseline
S6 phosphorylation was low and hardly affected by HBV (Fig. 7A),
HBsAg and HBcAg. Only HBeAg slightly increased S6 phos-
Figure 4. Monocytes support immune regulatory effect HBV on pDC. A: PBMC were stimulated with CpG with or without HepG2.215-
derived HBV. Data present mean6SEM frequencies of IFNa and TNFa producing pDC of 6 independent experiments. B: PBMC or pDC were cultured
with CpG with or without HepG2.215-derived HBV. Mean6SEM intracellular IFNa expression in pDC of 21 independent experiments is shown.
*p=0.01, **p,0.001, Wilcoxon signed rank test. C: PBMC were stimulated with CpG with or without HepG2.215-derived HBV and with or without
neutralizing antibodies to IL-10 or IL-10R. The percentages of IFNa producing pDC were determined by flow cytometry. The percentage of cytokine
producing pDC in control cultures was set on 1 and the relative production was calculated. Data demonstrate mean6SEM relative IFNa production
by pDC (n=3). DE: pDC were cultured alone or with monocytes (1:5) and stimulated with CpG either in the presence or absence of HepG2.215-
derived HBV (1000 geq/pDC). The percentage of IFNa (D) and TNFa (E) producing pDC were determined by flow cytometry. Due to large variation
between donors, the percentage of cytokine producing pDC in control pDC cultures was set on 1 and the relative cytokine production was
calculated. Wilcoxon signed rank tests were performed on original data, *P,0.05 (n=6).
doi:10.1371/journal.pone.0015324.g004
of 8 independent experiments. EFG: Purified pDC were stimulated with CpG in the presence or absence of patient serum-derived HBV. Healthy
control serum was treated in a similar way and added in the same volume to pDC. After 24h, supernatants were harvested and tested for the
presence of IFNa (E), TNFa (F) and IL-6 (G) by ELISA. Shown is the mean6SD of triplicate cultures from one out of 2 experiments with different donors.
HI: NK cells were cultured with or without pDC and with or without HepG2.215-derived HBV in medium containing IL-3 and CpG. Data show
mean6SEM CD25 expression on CD56+ cells (E) and IFNc production (F) of 7 independent experiments. *p,0.05, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0015324.g003
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expected, CpG strongly increased S6 phosphorylation (Fig. 7A),
which was significantly inhibited by HBV and HBsAg, but not by
HBcAg or HBeAg (Fig. 7AB). Also TLR7 triggering induced
phosphorylation of S6, but in contrast to TLR9 stimulation,
neither HBV nor HBsAg significantly affected Lox-induced S6
phosphorylation (Fig. 7C).
TLR9 triggering increases pDC-HBsAg interaction
Of course, the lack of inhibitory effects of HBV and HBsAg on
Lox-induced S6 phosphorylation is completely in line with the
absence of immune regulatory effects of HBV and HBsAg on Lox-
induced pDC function. However, in case HBV actively induces a
regulatory signalling molecule able to inhibit TLR9 signalling, e.g.
SOCS proteins, these inhibitory proteins often block both TLR7
Figure 5. HBsAg and HBeAg inhibit cytokine production by pDC. pDC were cultured with CpG in the presence or absence of increasing
doses or 5 mg/ml of HBcAg, HBeAg or HBsAg. Supernatants were harvested and analysed for IFNa (A), TNFa (B), IP-10 (C), IL-6 (D), and IL-8 (E). Data
presented are mean6SEM of at least 8 independent experiments. *P,0.05, Wilcoxon signed rank test compared to control.
doi:10.1371/journal.pone.0015324.g005
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similar.
Therefore, the specific inhibition of TLR9-induced function
may be more related to specific interaction of HBV and HBsAg
with TLR9-stimulated pDC rather than the induction of a specific
immune regulatory protein. To investigate the interaction between
HBsAg, either as part of the viral envelope or single circulating
protein, and pDC was examined by culturing pDC with or
without CpG or Lox either in the presence or absence of HBsAg
for 4h. In addition, cells were stimulated with CpG and Lox for 2h
at 37uC, then cells were put on ice and HBsAg was added.
Subsequently, pDC surface binding of HBsAg was determined. In
both types of experiments, no or only a very low binding of HBsAg
was observed in cultures with medium alone and Lox, whereas
pDC stimulated with CpG strongly bound the HBV envelope
protein (Fig. 8A). Hence, it is tempting to speculate that the
preferential binding of HBsAg to CpG-stimulated pDC is
responsible for the ability of the virus to interfere especially with
CpG-induced pDC function.
Recently, BDCA-2 was proposed as receptor involved in pDC-
HBsAg interaction leading to active inhibition of pDC function
[14]. However, in contrast to HBV (Fig. 2A) and HBsAg (data not
shown), BDCA-2 crosslinking also inhibited HSV-induced pDC
function (Fig. 8B) as described previously [21]. In addition, the
negligible interaction between HBsAg and non-stimulated pDC
and the increased binding of HBsAg to CpG-activated pDC are in
contrast to the high expression of BDCA-2 on non-stimulated
cells, which is even downregulated to a limited extent upon
activation (Fig. 8C) [21]. In this experimental setup, HBsAg
binding was not significantly inhibited by the addition of anti-
BDCA-2 antibodies (Fig. 8D). These data suggest that a CpG-
induced co-factor, but not BDCA-2, is involved in the increased
binding of HBsAg to pDC.
Discussion
pDC play a central role in anti-viral immunity due to their rapid
and profound release of type I IFN upon viral recognition. We
demonstrated that HBV does not activate pDC as assessed by
cytokine production and co-stimulatory molecule expression.
Moreover, HBV interfered with TLR9-induced pDC function,
resulting in dose-dependent inhibition of cytokine production and
pDC maturation. HBsAg, and to a limited extent HBeAg, which
were used in concentrations found in hepatitis B patients’
circulation [18], showed similar immune regulatory effects as
HBV thereby demonstrating that the immune regulatory effects of
HBV do not require active infection.
The lack of a detectable initial type I IFN response in patients
upon HBV infection is not understood so far [5,6]. With the
exception of a marginal elevated expression of HLA-DR in the
presence of HBV, which may lead to enhanced DC-T cell
interactions and viral immunity, the overall inability of HBV to
activate pDC may underlie this defective innate immune response.
Since pDC possess several pattern recognition receptors that are
mainly located intracellular, the lack of pDC activation by HBV
could be due to the fact that HBV is not taken up by pDC. This
does not rule out the possibility that HBV indirectly activates
immune receptors in/on pDC, e.g. by uptake of infected
hepatocytes or crosstalk with other immune cells.
The finding that HBV-DNA could be detected in peripheral
blood pDC of a subset of chronic HBV patients [15,16] indicates
direct interaction between pDC and HBV in vivo. The lack of pDC
activation upon exposure to HBV supports the hypothesis that
HBV behaves as a ‘‘stealth’’ virus and does not induce IFN-related
genes during acute infection [5]. However, our data also support
ideas that HBV possesses immunosuppressive strategies to evade
the initial response that could be elicited by the innate immune
system of the host. The decreased CpG-induced IFNa production
by pDC exposed to HBsAg is in line with a recent study [14]. Here
we showed that HBsAg not diminishes all pDC functions, but
HBsAg and HBV inhibit more than only IFNa production. Not
only the direct anti-viral activities, i.e. the production of cytokines,
but also other important more indirect anti-viral immune
parameters were influenced by HBV. pDC maturation, important
for pDC-T cell crosstalk, was strongly impaired and pDC-induced
NK cell function was also significantly diminished. The impaired
crosstalk between different immune cells may partially explain the
failing induction of effective anti-viral immunity. Whether the
impaired DC-NK cell crosstalk could explain the defective IFNc
production by NK cells circulating in patients with chronic
hepatitis B [22,23] remains unknown.
Of relevance, next to HBsAg and HBV also HBeAg showed
immune regulatory effects on pDC. Immunosuppressive effects of
the whole virion, as well as HBsAg and HBeAg, have also been
reported for TLR3 and TLR4-mediated innate immunity of
murine hepatocytes and non-parenchymal liver cells [24,25]. The
lack of direct pDC activation combined with the inhibitory effect
of HBV on the innate immune function of pDC, as well as other
intrahepatic cells, may contribute to the enhanced risk of viral
persistence upon infection with HBV compared to other viruses
such as Influenza. Nevertheless, infection with HBV at adult life
most often leads to self-limited acute hepatitis B. This could be
explained by direct and/or indirect immune stimulatory effects of
HBV towards other cells of the immune system, such as recently
demonstrated for Kupffer cells [26]. It is likely that in most HBV-
infected adults these immune stimulatory processes overrule the
inhibitory effects of the virus leading to adequate anti-HBV
specific immunity.
Table 2. Patient characteristics.
N Sex (%) Age (yr) HBV-DNA (Log10 IU/mL) ALT (IU/L)
F/M Mean±SEM Mean (Range) Mean±SEM
Healthy controls 21 48/52 33.561.7 n.a. n.d.
Chronic HBV 25 44/56 33.562.1 6.8 (#3.0–10.4) 141651
HBeAg
pos 15 47/53 31.663.0 7.9 (#3.0–10.4) 188681
HBeAg
neg 10 40/60 36.562.6 5.2 (#3.0–9.8) 70632*
n.a., not applicable; n.d., not determined;
*HBeAg
pos vs HBeAg
neg, P,0.05.
doi:10.1371/journal.pone.0015324.t002
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e15324Figure 6. Chronic HBV patients display impaired CpG-induced pDC function. Frozen PBMC from patients (HBV; n=25) and healthy controls
(HC; n=21) were thawed, washed and cultured in the absence or presence of CpG or Lox and investigated for the production of IFNa by ELISA (AB) or
intracellular flow cytometry (CDE) as described in Materials and Methods. For additional analysis of the CpG-induced IFNa producing capacity, the
patient group was divided into HBeAg-positive (n=15) and HBeAg-negative (n=10) disease. Shown are the mean6SEM IFNa production by HC and
patients (A–D) and the relation between serum ALT levels and IFNa producing pDC within the total patient group as defined by Spearman’s
correlation coefficient. *Mann-Whitney U test, P,0.05.
doi:10.1371/journal.pone.0015324.g006
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HBV, as demonstrated by inhibition of S6 and IRF7 phosphory-
lation and production of IFNa, TNFa, IL-6 and IP-10. HBeAg
impaired pDC function to a much lesser extent and seemingly via
another yet unknown intracellular signalling mechanism. At what
level HBV and HBsAg interfere with mTOR-induced S6
phosphorylation remains to be elucidated. Several putative binding
factors have been described for HBsAg, but their exact role in HBV
attachment remains unclear [27–29]. The increased binding of
HBsAg to CpG-stimulated pDC suggests the involvement of a
TLR9-induced co-factor, either membrane bound or soluble, that
scavengesHBV/HBsAg.WhetherTLR9 triggering occursinHBV-
infected individuals is not known. It is tempting to speculate that
pDC could be indirectly activated by HBV via interaction with
viable or dead HBV-infected cells that contain viral DNA able to
trigger TLR9, but also other HBV-related or even unrelated
activation signals may induce the expression of this scavenging co-
factor. Differential expression of this factor, e.g. related to different
disease states or host polymorphisms, may influence pDC function
and the regulation of virus-specific immunity.
Since HBV surface antigens are glycoproteins, the involvement
of a C-type lectin seems plausible. Crosslinking of the pDC-specific
C-type lectin DC immunogenic receptor (DCIR) resulted in a
specific TLR9, but not TLR7-mediated inhibition of TNFa and
Figure 7. HBV and HBsAg inhibit CpG-induced S6 phosphorylation. A: pDC were cultured with CpG in the presence or absence of
HepG2.215-derived HBV. Data show the expression of phosphorylated S6 and the mean fluorescence intensity (MFI) and are representative for 8
independent experiments. B: pDC were cultured with or without CpG in the presence or absence of HBcAg, HBeAg, or HBsAg. Data show expression
of phosphorylated S6 and the MFI and are representative for 3 independent experiments. C: Data show mean6SEM expression of phosphorylated S6
in BDCA4
+CD123
+ pDC in PBMC exposed to CpG or Lox in the presence or absence of HepG2.215-derived HBV from 6 independent experiments.
*p,0.05, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0015324.g007
HBV Inhibits Plasmacytoid Dendritic Cell Function
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e15324IFNa [30], which is compatible to the immune modulatory effects
observed for HBV. Nevertheless, these C-type lectins are often
highly expressed on non-stimulated pDC and downregulated by
TLR7 and TLR9 triggering to a similar extent as was observed for
BDCA-2 [21], which is in contrast to the observed increased
interaction between HBV and pDC upon CpG stimulation.
Altogether, we cannot confirm the binding of HBsAg to BDCA-2
to explain the inhibitory effect of HBsAg on pDC function as
suggested before [14], which indicates that there is at least also
another receptor involved. Several other viruses, including HCV
and HIV, have been shown to block TLR9-induced pDC
function, but not TLR7-mediated activation [31]. These viruses
may crosslink similar cellular/soluble receptors as HBV, but
whether they also preferentially bind to TLR9/CpG-activated
pDC is not documented.
In line with our in vitro observations that HBV significantly
interferes with CpG-induced, but hardly affects Lox-induced pDC
function, also chronic HBV patients displayed a significant defect
in CpG-induced, but not Lox-induced IFNa production by pDC
compared to healthy controls. Impaired pDC function, mainly
investigated upon exposure to TLR9 ligands, has been reported in
several other studies (reviewed in Woltman et al. [13]) and has
recently been associated with decreased TLR9 expression levels in
chronic HBV [32]. Whether decreased TLR9 expression levels
explain the specific impairment in CpG-induced IFNa production
as demonstrated in the present study remains to be elucidated.
Previously, the loss of serum HBeAg during anti-viral treatment of
patients has been suggested to be responsible for partial restoration
of IFN-a production by pDC [33,34]. In line, we here observed
that especially HBeAg-positive chronic HBV patients displayed
impaired pDC function compared to HBeAg-negative patients
and healthy controls. These findings may be ascribed to the
inhibitory effects of HBeAg on IFNa and TNFa production by
pDC and at least fit with the idea that HBeAg possesses immune
Figure 8. HBsAg preferentially binds to CpG-activated pDC. A: pDC were cultured with or without Lox or CpG and with or without HBsAg.
After 4h, cells were harvested and surface bound HBsAg was detected by flow cytometry. Data are representative for 5 independent experiments.
Open: HBsAg detection in cultures without HBsAg; Filled: HBsAg detection in cultures with HBsAg. B: PBMC were cultured in the presence of CpG, Lox
or HSV-1 either with or without anti-BDCA-2 or BDCA-4. IFNa production in pDC was detected by flow cytometry. Data show mean6SD relative IFNa
production compared to cultures without BDCA-2/4 crosslinking for 2 independent experiments. C: pDC were cultured with or without CpG or Lox
for 24h. Data show mean6SEM BDCA-2 expression as assessed by flow cytometry of 5 independent experiments. NS: not significant. D: PBMC were
cultured with or without CpG and with or without HBsAg. After 4h, cells were harvested and surface bound HBsAg was detected on pDC by flow
cytometry. Data show mean6SEM HBsAg positive pDC of 5 independent experiments.
doi:10.1371/journal.pone.0015324.g008
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showed higher serum ALT levels compared to the HBeAg-
negative patients. Serum ALT levels inversely correlated with
pDC function, which indicates that also other regulatory
mechanisms than the virus itself may influence pDC function.
Despite a significant inhibitory effect of HBV on pDC, both in vitro
and in vivo, their function is only partially diminished and hence
prevents HBV-infected individuals from generalized immune
suppression. As also discussed elsewhere [13], the interaction
between HBV and a subset of the total DC pool may have
profound effects on the induction of specific anti-HBV immunity,
but the functionality of the total DC pool and the immunocom-
petence of the patient seems to be retained albeit to a somewhat
lower extent compared with healthy individuals.
In addition to the direct effect of HBV on pDC, HBV seems also
able to indirectly influence pDC function by interfering with
monocyte-pDC interaction.Whereas monocytesenhancedcytokine
production by pDC under control conditions, monocytes where
unable to do so in the presence of HBV. Since in contrast to HCV,
we neither detected HBV-induced TNFa or IL-10 in monocytes
(data not shown) nor restored HBV-induced regulation by IL-10
neutralization, it is tempting to speculate that HBV abrogates this
monocyte-induced pDC function by interfering with monocyte-
pDC interaction rather than active induction of an immune
regulatory factor by monocytes. Of note, interaction between
HBV/HBsAg and monocytes have been reported [36], but the
mechanism underlying monocyte-mediated regulation of pDC
function is not known.
Since a considerable number of patients chronically infected
with HBV do not demonstrate an adequate anti-HBV response
upon treatment with standard immune modulatory therapy, novel
anti-viral strategies are needed. For the treatment of chronic
HCV, promising results were obtained with the TLR9 agonist
CpG10101 [37]. The finding that HBV strongly interacts with
CpG-activated cells may disrupt the anti-viral effects of such
immune stimulating agents. Therefore, the data presented here
not only provide new insight into the mechanism by which HBV is
able to evade anti-viral immunity, but they may also aid in the
development of effective immunomodulatory therapies for the
treatment of chronic HBV.
Materials and Methods
HBV, proteins and TLR ligands
HepG2.215-derived HBV particles were purified and quantified
as described before [38] and unless indicated otherwise used at 100
or 2000 geq/cell for PBMC and pDC cultures, respectively. As a
negative control, the sameprocedure was followed with supernatant
fromuntransfectedHepG2cells.Additionally,patient-derivedHBV
was purified from serum of a chronic HBV patient (genotype B,
viral load 3.28610
9 IU/ml) using the same procedure. Serum of a
healthy control was treated similarly and was used as a control.
Recombinant Chinese Hamster Ovary cell (CHO-)derived HBsAg
and HBeAg or HBcAg derived from E. coli (Prospec, Rehovot,
Israel) were used at 5mg/ml and added, like the HBV particles,
either in the absence or presence of PolymyxinB (50 mg/ml; Sigma-
Aldrich, St. Louis, MO). G.M.G.M. Verjans and G.F. Rimmelz-
waan (both Dept of Virology, Erasmus MC) provided HSV-1 (MOI
10) and Influenza virus (H1a, MOI 0.2), respectively. Synthetic
TLR ligands included CpG-2336 (10 mg/ml, Coley Pharma,
Du ¨sseldorf, Germany) and Loxoribine (Lox 0.4 mM, Invivogen,
San Diego, CA). In all experiments, HBV or viral proteins were
added right before the addition of synthetic TLR ligands or other
pDC-stimulating agents.
Patients and healthy subjects
Peripheral heparinized blood samples were obtained from 25
patients with chronic hepatitis B (Table 2). All patients were
negative for antibodies against hepatitis C, hepatitis D and human
immunodeficiency virus, and did not receive treatment at time of
blood donation. A matched control group comprised 21 healthy
subjects. The study was approved by the local ethics committee,
and all patients and controls in the study gave informed consent
before blood donation.
Cell purification and culture
PBMC and pDC were isolated from peripheral heparinized
blood samples or buffy coats from healthy blood donors using
Ficoll density gradient centrifugation. All healthy controls gave
written informed consent before blood donation and the
institutional medical ethical committee gave declaration of no
objection for this study. pDC were isolated by CD19+ cell
depletion, anti-Blood Dendritic Cell Antigen (BDCA-4)-PE and
anti-PE MACS microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) or FACSorting (FACS Aria, Beckton Dickinson,
Alphen a/d Rijn, The Netherlands). Purity and viability (both
.95%) were checked using anti-BDCA2-FITC (Miltenyi) and 7-
AAD (eBioscience, San Diego, USA) by flow cytometry.
Monocytes were purified with anti-CD14 MACS microbeads
and MS-columns (Miltenyi). 1610
5 pDC, isolated by FACsorting,
were co-cultured with NK cells, isolated from the same donor with
an NK cell isolation kit (Miltenyi Biotec, Germany), in a 1:5 ratio
in RPMI 1640 containing 10% FCS, penicillin/streptomycin,
Hepes, IL-3 and CpG either with or without HBV (200 geq/pDC)
for 48h.
Flow cytometric analysis: Surface markers and signalling
molecules
pDC were stained with anti-BDCA4-PE, anti-BDCA-2-FITC,
anti-CD80-FITC (MAB104; Immunotech, Marseilles, France),
anti-CD123-biotin (BD Pharmingen, USA), anti-HBsAg-FITC
(Acris Antibodies GmbH, Hiddenhausen, Germany), anti-CD86-
APC (2331), anti-HLA-DR-PerCP (243), anti-CD40-APC (5C3)
and/or streptavidin-PerCP (all BD Biosciences) in PBS/1%FCS/
0.02%NaN3. HBsAg binding experiments were performed in the
presence or absence of 5mg/ml anti-BDCA2-biotin or anti-
BDCA4-PE. NK cells were stained with antibodies directed
against CD56 (MY31) and CD25 (2A3, all BD Bioscience).
Corresponding isotype-matched control antibodies were used to
determine background staining.
To determine intracellular signalling, PBMC (1610
6 cells/
250 ml) or pDC (5610
3 cells/250 ml) were stimulated at 37uC.
After 5–180 min, cells were fixed with 2% formaldehyde, washed
with PBS/1%FCS/0,02%NaN3 and incubated with 0,5% sapo-
nin. Antibodies against Phospho-S6 (pSer235/236, Bioke ´, Leiden,
The Netherlands) and phospho-Interferon regulatory factor-7 (P-
IRF7; pS477/pS479; K47-671, BD Biosciences) followed by goat-
anti-rabbit-biotine (Dako, Glostrup, Denmark) were diluted in
0,5% saponin and added for 15 minutes. Finally, cells were stained
with streptavidin-PerCP (BD Biosciences).
Cells were analysed by flow cytometry (FACS CantoII or
FACScalibur) and FACS Diva or CellQuest Pro software (all
Beckton Dickinson, Alphen a/d Rijn, The Netherlands).
Cytokine production
PBMC (1610
6 cells/ml) or pDC (2610
4 cells/ml) were
resuspended in RPMI 1640 (Lonza, Basel, Switzerland) containing
10% heat-inactivated FCS (Hyclone, Logan UT), 100U/ml
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IL-3 (20ng/ml, Miltenyi). Neutralizing antibodies (5mg/ml) to IL-
10 or IL-10 receptor (IL-10R; both from BD Pharmingen) were
added where indicated. 24h culture supernatants were examined
for TNF-a (eBioscience), IL-6 (Biosource International, Nivelles,
Belgium), IL-8 (Biosource), IP-10 (Invitrogen) and IFNa (Bender
Medsystems, Vienna, Austria) by ELISA. IFNc production by NK
cells was also determined by ELISA (eBioScience). The frequen-
cies of IFNa and TNFa producing pDC were quantified by
incubating cells during the last 3h of 5h cultures with 10mg/ml
Brefeldin A (Sigma-Aldrich). Cells were fixed and permeabilized
with Intraprep (Beckman Coulter, Miami, Florida, USA) and
stained with anti-IFNa-FITC (Kordia, Leiden, The Netherlands),
anti-TNFa-APC (Caltag-Medsystems, Buckingham, UK) and
pDC-specific antibodies as described above.
Quantitative RT-PCR
Cells were lysed in Trizol (Sigma-Aldrich) and stored at 280uC
until further use. RNA was precipitated with 75% ethanol and
isolated using RNeasy mini colums (Qiagen, Venlo, The Nether-
lands). cDNA was synthesized with iScript cDNA synthesis kit
(BioRad laboratories BV). Real-time PCR was performed with the
following primer pairs: GAPDH_F 59-AGG TCG GTG TGA
ACG GAT TTG-39 and GAPDH_R 59TGT AGA CCA TGT
AGT TGA GGT CA-39, IFNa2_F 59-AAT GGC CTT GAC
CTT TGC TT-39 and IFNa2_R 59-CAG CTT GAC TTG CAG
CTG AG-39, IFNa8_F 59-TGG TGC TCA GCT ACA AGT
CAT T-39 and IFNa8_R 59-TAC CCA GGC TGT GAG TCT
GA-39 under standard conditions (annealing temperature 63uC;
40 cycli; MyIQ iCycler, Biorad). IFNa gene expression was
normalized to GAPDH and calculated using the DDCT method
[39].
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